Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

250.39USD
8:59pm BST
Change (% chg)

$2.16 (+0.87%)
Prev Close
$248.23
Open
$248.29
Day's High
$251.29
Day's Low
$247.75
Volume
77,481
Avg. Vol
299,559
52-wk High
$253.69
52-wk Low
$191.53

Chart for

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $45,076.07
Shares Outstanding(Mil.): 227.57
Dividend: 0.73
Yield (%): 1.47

Financials

  BDX.N Industry Sector
P/E (TTM): 56.67 32.29 32.76
EPS (TTM): 3.50 -- --
ROI: 2.84 13.92 14.61
ROE: 7.36 16.77 16.33

U.S. investigates bloodstream infections for link to heparin syringes

SHANGHAI/CHICAGO Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.

11 May 2018

U.S. investigates bloodstream infections for link to heparin syringes

* 14 children in 4 states have confirmed bloodstream infections

11 May 2018

BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19

* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE

03 May 2018

BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering

* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:

26 Apr 2018

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

22 Mar 2018

BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical

* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS

19 Mar 2018

BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe

* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS

20 Feb 2018

BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes

* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING

16 Feb 2018

Earnings vs. Estimates